Evidence map›Paper›PMID 35289038›Full record

ArticleEuropean journal of heart failure2022

Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get With The Guidelines-Heart Failure registry.

Neil Keshvani, Anurag Mehta, Heather M Alger, Christine Rutan, Joseph Williams, Shuiaqi Zhang, Rebecca Young, Brooke Alhanti, Karen Chiswell, Stephen J Greene and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Observational
  13. COVID-19 and heart failure: the dark side of the moon.European journal of heart failure · 2022
    Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Neil KeshvaniDivision of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Anurag MehtaDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Heather M AlgerAmerican Heart Association, Dallas, TX, USA.
Christine RutanAmerican Heart Association, Dallas, TX, USA.
Joseph WilliamsAmerican Heart Association, Dallas, TX, USA.
Shuiaqi ZhangDuke Clinical Research Institute, Durham, NC, USA.
Rebecca YoungDuke Clinical Research Institute, Durham, NC, USA.
Brooke AlhantiDuke Clinical Research Institute, Durham, NC, USA.
Karen ChiswellDuke Clinical Research Institute, Durham, NC, USA.
Stephen J GreeneDuke Clinical Research Institute, Durham, NC, USA.
Adam D DeVoreDuke Clinical Research Institute, Durham, NC, USA.
Clyde W YancyDivision of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Gregg C FonarowAhmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, CA, USA.
Ambarish PandeyDivision of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo assess heart failure (HF) in-hospital quality of care and outcomes before and during the COVID-19 pandemic. METHODS AND

resultsPatients hospitalized for HF with ejection fraction (EF) <40% in the American Heart Association Get With The Guidelines©-HF (GWTG-HF) registry during the COVID-19 pandemic (3/1/2020-4/1/2021) and pre-pandemic (2/1/2019-2/29/2020) periods were included. Adherence to HF process of care measures, in-hospital mortality, and length of stay (LOS) were compared in pre-pandemic vs. pandemic periods and in patients with vs. without COVID-19. Overall, 42 004 pre-pandemic and 37 027 pandemic period patients (median age 68, 33% women, 58% White) were included without observed differences across clinical characteristics, comorbidities, vital signs, or EF. Utilization of guideline-directed medical therapy at discharge was comparable across both periods, with rates of implantable cardioverter defibrillator (ICD) placement or prescription lower during the pandemic (vs. pre-pandemic period). In-hospital mortality (3.0% vs. 2.5%, p <0.0001) and LOS (mean 5.7 vs. 5.4 days, p <0.0004) were higher during the pandemic vs. pre-pandemic. The highest in-hospital mortality during the pandemic was observed among patients hospitalized in the Northeast region (3.4%). Among patients concurrently diagnosed with COVID-19 (n = 549; 1.5%), adherence to ICD placement or prescription, prescription of aldosterone antagonist or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor at discharge were lower, and in-hospital mortality (8.2% vs. 3.0%, p <0.0001) and LOS (mean 7.7 vs. 5.7 days, p <0.0001) were higher than those without COVID-19.

conclusionAmong GWTG-HF participating hospitals, patients hospitalized for HF with reduced EF during the pandemic received similar care quality but experienced higher in-hospital mortality than the pre-pandemic period.

Indexed as

COVID-19Heart FailureAgedFemaleHospitalizationHospitalsHumansMalePandemicsQuality of Health CareRegistriesUnited StatesCOVID-19Heart failureOutcomesQuality of care

Identifiers

PMID35289038
PMCPMC9087396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.